[ SAKK / Calgene - HEM Pioneer Grant to Fight Blood Cancer | Research funding ]

The Swiss Group for Clinical Cancer Research (SAKK) is a non-profit organization which has been conducting clinical trials in oncology since 1965. SAKK is a competence center in clinical cancer research for authorities, associations and pharmaceutical companies in Switzerland. 

Many types of blood cancer remain incurable and are associated with severe morbidity and increased mortality. SAKK’s HEM Pioneer Grant is funded by Celgene GmbH and aims to support projects and research that could potentially pave the way for a game changing outcome in the field of blood cancers.

Eligible Projects:

• intends to pave the way for a potentially game-changing impact in the field of hemato-oncological diseases including their premalignancies.
• has a research nature (e.g. clinical or translational research, database/registry research, working and patient care models, assessment tools, etc.).
• must not be a basic science project.
• may focus on aspects such as treatment approaches, mode of action of drugs, mode of disease, interdisciplinary communication/collaboration, etc.
• is conducted in Switzerland.
• is planned or ongoing.